Traditional antibiotics are reaching obsolescence as a consequence of antibiotic 27 resistance; therefore novel antibiotic approaches are needed. A recent non-traditional approach 28 involves formation of protein aggregates as antimicrobials to disrupt bacterial homeostasis. 29 Previous work on protein aggregates has focused on genome mining for aggregation-prone 30 sequences in bacterial genomes rather than on rational design of aggregating antimicrobial 31 peptides. Here, we use a synthetic biology approach to design an artificial gene encoding the first 32 de novo aggregating antimicrobial peptide. This artificial gene, opaL (overexpressed protein 33 aggregator Lipophilic), disrupts bacterial homeostasis by expressing extremely hydrophobic 34 peptides. When this hydrophobic sequence is disrupted by acidic residues, consequent 35 aggregation and antimicrobial effect decreases. Further, to deliver this artificial gene, we 36 developed a probiotic approach using RK2, a broad host range conjugative plasmid, to transfer 37 opaL from donor to recipient bacteria. We utilize RK2 to mobilize a shuttle plasmid carrying the 38 opaL gene by adding the RK2 origin of transfer. We show that opaL is non-toxic to the donor, 39 allowing for maintenance and transfer since its expression is under control of a promoter with a 40 recipient-specific T7 RNA polymerase. Upon mating of donor and recipient Escherichia coli, we 41 observe selective growth repression in T7 polymerase expressing recipients. This technique 42 could be used to target desired pathogens by selecting pathogen-specific promoters to control 43 opaL expression. This system provides a basis for the design and delivery of novel antimicrobial 44 peptides. 45 46 47 3 48 Importance 49
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Growth media included Luria Bertani (LB) broth (liquid medium) and LB agar (solid 163 medium) with selective antibiotics as described for each experiment. Liquid cultures were 164 incubated at 37°C in an orbital shaker or in a Tecan GENios plate reader. When using the plate 165 reader, cultures were set to shake for 10 minutes, stand idle for 10 minutes, and then shake for an 166 additional 10 seconds prior to taking a measurement. Solid cultures were grown in a stationary 167 incubator at 37°C. The opaL gene and the opaLacidic gene were induced using IPTG at 168 concentrations of 1.0 or 0.1 mM as described for each experiment. GFP from pHL662 and 169 mCherry from pUV145 were induced using IPTG at concentrations of 1.0 mM. Except where 170 otherwise noted, ampicillin was used to maintain pET11a-opaL and pET11a-opaLacidic and 171 kanamycin was used to maintain RK2, pHL662, and pUV145. DH5α alone were spotted onto 1.0 mM IPTG plates without selection and incubated for 5 h. We 302 cut out the solid agar slices with mating spots, transferred them each into 1 mL of PBS, and 303 vortexed thoroughly to resuspend the mated bacteria. These cells were diluted to 110 -5 and binding also disfavors acidic amino acids (28), seven aspartic acid residues were incorporated 324 into the highly hydrophobic OpaL sequence. These aspartic acids were all spaced at least twelve 325 residues apart from each other to minimally interfere with hydrophobicity-mediated aggregation.
326
Since protein half-life is strongly influenced by terminal amino acid sequences, several 327 protective polar amino acids (serine, asparagine, and threonine) were incorporated to avoid 328 degradation by proteases which vastly shorten half-lives by recognizing bulky terminal 329 hydrophobic residues (25). N-formylmethionine was still allowed at the N-terminus since, 330 although it is hydrophobic, N-formylmethionine promotes long protein half-lives (29). Since the 331 N-formylmethionine found in bacterial proteins is often cleaved by intracellular proteases, the 332 next several chosen residues were also among those that promote long half-lives. These design 333 parameters may also provide a general template for future variations of the OpaL peptide.
334
To verify that OpaL's antimicrobial activity arose mainly from its highly hydrophobic 335 character (75.1% hydrophobic amino acids), we created a similar 184 residue control peptide,
336
OpaLacidic, with greatly increased content of acidic amino acids. This peptide includes 30 337 aspartic acid residues comprising 16.3% of the sequence (supplementary Fig. S3 ). To facilitate 338 charge-charge repulsion and interfere with hydrophobic aggregation (from OpaLacidic's 70.7% 339 hydrophobic residues), these aspartic acids were placed every five residues over the majority of 340 the sequence. that inducing OpaL expression with 1.0 mM IPTG completely precluded growth ( Fig. 2A) .
349
When using 0.1 mM IPTG instead, OpaL expression still decreased mean OD (Fig. 2B) , though 350 some growth occurred. In absence of IPTG, BL21 (DE3) carrying pET11a-opaL showed a longer were observed with respect to the empty plasmid control ( Fig. 2A-B ). This could be attributed to 359 a metabolic burden from carrying the plasmid.
360
In colony forming unit (CFU) experiments, the viable cell counts of E. coli BL21 (DE3) 361 expressing OpaL dropped to zero after 4 hours of induction with 1.0 mM IPTG (p<0.01), 362 indicating a bactericidal mechanism of action ( Fig. 2D ). In the absence of IPTG, the viable cell 363 count continued to significantly increase over time. The viable cell counts after 2 hours and 4 364 hours for E. coli BL21 (DE3) carrying pET11a-opaLacidic were significantly lower with 1.0 365 mM IPTG than without any IPTG ( Fig. 2E) mean aggregation propensity of 0.7% (Fig. 3A, supplementary table S2 ). These data support the 379 idea that OpaL expression triggers the formation of lipophilic aggregates.
380
The QUARK algorithm, an ab initio protein structure prediction tool, was used to predict 381 the tertiary structural characteristics of OpaL and OpaLacidic. DeepView was employed to 382 visualize these structures and to compute their solvent-exposed hydrophobic surface areas. OpaL 383 was predicted to be rich in β-sheet structures (Fig. 3B ). By contrast, OpaLacidic was almost 384 entirely composed of unstructured loops (Fig. 3C) has been shown to mobilize shuttle plasmids from donor to recipient E. coli and from donor E. 428 coli to recipient P. aeruginosa with conjugation frequencies of 8 and 0.2 transconjugants per 429 donor (respectively) (43). The RK2 plasmid can be transferred among most gram-negative and 430 many gram-positive bacteria and has even been shown to move from prokaryotic to eukaryotic 431 cells, albeit at a much lower frequency (39, 41) . Additionally, RK2 is known to be a stable 432 plasmid as result of active partitioning, post-segregational killing, and multimer resolution (44).
433
Active partitioning involves NTPases which transport copies of the plasmid to opposite poles of 434 the cell prior to division (45). Post-segregational killing utilizes a slowly degraded toxin and 435 rapidly degraded antidote. If the antidote's production ceases as a result of plasmid loss, the 436 toxin remains in the cell for longer than the residual antidote and the cell loses viability (46). In 437 multimer resolution, resolvases correct plasmid multimers formed by recombination (44). These 438 20 characteristics allow RK2 to rapidly spread plasmid DNA through bacterial populations. RK2 439 encodes relaxosome and transferosome proteins to mediate conjugative transfer (Fig. 4A) . The 472 We mated donor E. coli C600 carrying RK2 and pET11a-opaL plasmids with recipient E. 473 coli BL21 (DE3) carrying the pHL662 plasmid (which expresses GFP) using 1:3 donor to 474 recipient ratios based on optical density in presence of 1.0 mM IPTG. As a control, we also 475 performed these matings using donors that carried only the RK2 plasmid under similar 476 conditions. After the matings had been completed, the cultures were diluted and spread on fresh 477 solid medium containing 1.0 mM IPTG. Using fluorescent protein expression to distinguish 478 between strains (supplementary Fig. S2A ), we calculated the ratios of recipient colonies to total 479 colonies. The experimental group's recipient CFU fractions were 2.0-fold lower than those in the 480 mating control (p<0.01), demonstrating successful opaL delivery and toxicity (Fig. 4B) to the control without pET11a-opaL ( Fig. 4C ). After 20 hours of growth, the mean fluorescence 485 value of the experimental group was 1.5-fold lower than that the control (p<0.001). evolution. Since OpaL's mechanism depends on persistent "misfolding" and aggregation rather 517 than fixed tertiary folds, mutations should be less likely to decrease OpaL's activity, widening 518 the pool of potentially improved mutants as compared to most protein therapeutics (53). After 519 iterated mutagenesis and screening, this scenario's opaL gene may regain activity against 520 resistant pathogens. Furthermore, as hydrophobic aggregation can occur in any aqueous cellular 521 environment, OpaL's mechanism may enable activity in diverse types of targeted bacteria.
OpaL kills recipient cells in the two-strain mating experiment
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We also demonstrate an assembly of biological components to develop a mobile genetic 523 system which eliminates promoter-targeted strains within bacterial populations. We employed 524 the highly efficient RK2 plasmid to mobilize our pET11a-opaL shuttle vector and spread opaL 525 through populations of bacteria. Our RK2 mediated delivery system has promise for treating 526 infections which involve biofilms. The rate of bacterial conjugation tends to be much higher in 527 biofilms (which pathogenic bacteria such as E. faecalis and P. aeruginosa frequently form) (54, 528 55) than in laboratory culture conditions. Of particular note, Hausner and Wuertz showed that 529 conjugative transfer increases up to 1,000-fold when using RK2 derived plasmids in biofilms 530 24 (56). In large part, this occurs because cells within biofilms are immobilized and consequently 531 form more stable conjugative junctions (57). We envision pathogenic biofilms providing a rich 532 conjugative environment for opaL propagation. Donor bacteria with similar surface 533 characteristics to the target pathogens might be capable of integrating into biofilms. OpaL's 534 effectiveness could be tested in the future using pathogenic bacteria such as P. aeruginosa under 535 biofilm forming conditions. Our de novo design approach for an aggregating antimicrobial 536 peptide may be adaptable to many types of infections, yet possess specificity in its targeting of 
